Randomized open-label trial of dextromethorphan in Rett syndrome

Conclusions: Dextromethorphan is a potent noncompetitive antagonist of the NMDA receptor channel that is safe for use in young girls with Rett syndrome. Preliminary evidence suggests that dextromethorphan may improve some core features of Rett syndrome. Classification of evidence: This study provides Class IV evidence that dextromethorphan at various doses does not change EEG spike counts over 6 months, though precision was limited to exclude an important effect.

http://www.neurology.org/cgi/content/short/89/16/1684?rss=1

Source: Neurology - October 16, 2017 Category: Neurology Authors: Smith-Hicks, C. L., Gupta, S., Ewen, J. B., Hong, M., Kratz, L., Kelley, R., Tierney, E., Vaurio, R., Bibat, G., Sanyal, A., Yenokyan, G., Brereton, N., Johnston, M. V., Naidu, S. Tags: Clinical trials Observational study (Cohort, Case control), Rett Syndrome, All Genetics ARTICLE Source Type: research